Inseego Offers the Industry's First 5G Cloud WAN Solution to Enterprises
19.7.2022 14:01:00 EEST | Business Wire | Press release
Inseego Corp. (Nasdaq: INSG), a leader in 5G edge cloud solutions, today announced the release of Inseego 5G SD EDGE™ for enterprises, a 5G cloud networking solution that delivers networking and security through a 5G network fabric, thereby eliminating the need for complex, expensive, on-premise custom legacy hardware solutions. The Inseego 5G SD EDGE cloud enables the industry's first zero trust network access (ZTNA) solution with distributed security and granular IT control designed exclusively for 5G networks. This new solution follows a novel approach to create a thin edge that is cloud controlled and makes digital transformation simple, fast, and affordable for enterprises of all sizes.
The pandemic revolutionized the workplace, and as a result, enterprises worldwide are seeking cost-effective solutions to securely connect their distributed sites and workforce. There has been a lack of innovation regarding this trend, and the current market solutions are not equipped to scale the growing remote workforce. Inseego’s 5G SD EDGE was designed specifically to address this need as it provides a cost-effective solution that can scale quickly into thousands of distributed locations fully controlled by corporate IT security protocols.
Inseego's 5G SD EDGE solution enables enterprises to deliver better and more secure experiences to their employees and distributed sites, irrespective of their locations.
- 5G WWAN: Inseego's 5G SD EDGE leverages Inseego’s entire industry-leading 5G FWA portfolio and delivers gigabit speeds at the edge over a secure 5G Wireless WAN (WWAN) that can be deployed in minutes anywhere around the world.
- Extend corporate Wi-Fi across a distributed enterprise: The solution extends the plug-and-play corporate LAN experience to remote worker homes and distributed company sites, resulting in reliable and secure 5G connectivity at the edge, wherever business happens.
- Automate and orchestrate processes for simplified, responsive and efficient IT: Corporate IT departments can easily manage and configure network traffic prioritization, device management, and security from a single pane of glass with unified policies and compliance.
- Secure the distributed edge: The Inseego 5G SD EDGE solution extends corporate IT with ZTNA components for the first time into the 5G network fabric, providing inherent security, encryption, tunneling, authentication, threat prevention, and much more.
- Cost savings: Most traditional IT networks comprise piecemeal components from multiple legacy vendors, such as SD-WAN, connectivity, security, and networking, resulting in more costly and labor-intensive operation compared with an integrated wireless solution. Inseego 5G SD EDGE integrates 5G, wired connections, security, and networking functions, such as segmentation, traffic prioritization, load balancing, and other features, into a single solution, resulting in lower costs.
“Today, the demand for real-time experiences and tightened security is greater than ever, since business is happening everywhere, not just in the corporate office. When it comes to meeting that demand, a 5G WWAN corporate IT network is far more robust than any wired network for consistent and reliable IT and OT experiences at the edge,” said Ritesh Mukherjee, Senior Vice President & General Manager, Enterprise Networks at Inseego. “The release of the Inseego 5G SD EDGE cloud networking solution is a major innovation for the IT solutions world, which currently comprises of disparate and modular components that are pieced together by pricey vendors and designed to support a wired world, with wireless considered an add-on for backhaul. Inseego’s innovation brings SD-WAN, ZTNA, bonding of multiple wireless and wired connections, and remote management capabilities to 5G WWAN networks in a simple package for a fraction of the cost of traditional, modular solutions.”
“The number of distributed sites and remote workforces is unprecedented and has affected not only the way we work, but how IT organizations are evolving the corporate IT network. They are seeking to provide the corporate Wi-Fi experience to wherever business happens, which means excellent, reliable connectivity delivering gigabit performance and security beyond encryption that is just as robust outside as it is on-premise,” said Ray Mota, CEO and principal analyst of ACG Research. “By integrating ZTNA with a robust 5G cloud WAN, Inseego’s 5G SD EDGE solution is transforming enterprise cloud networking for IT organizations. By eliminating the need for reliance on traditional broadband connections, clunky piecemeal solutions, and security that enables risk-appropriate access to resources from any device at any time and from any location, Inseego has made a 5G-enabled enterprise a reality.”
The Inseego 5G SD EDGE solution is currently in trials with Fortune 500 enterprise customers in target markets. It is subscription-based and available globally through channel partners and directly to enterprises. For more information, visit: https://inseego.com/solutions/remote-employees/.
About Inseego Corp.
Inseego Corp. (Nasdaq: INSG) is an industry leader in intelligent device-to-cloud solutions that extend the 5G network edge, enabling broader 5G coverage, multi-gigabit data speeds, low latency, and strong security to deliver highly reliable internet access. Inseego's mobile broadband, fixed wireless access (FWA) solutions, and software platform incorporate the most advanced technologies (including 5G, 4G LTE, Wi-Fi 6, and others) into a wide range of innovative products that provide robust connectivity indoors, outdoors and in the harshest industrial environments. Inseego's products and SaaS solutions that provide the highest quality wireless connectivity for service providers, enterprises, and government entities worldwide are designed and developed in the USA. www.inseego.com #Putting5GtoWork
©2022. Inseego Corp. All rights reserved. The Inseego name and logo and Inseego 5G SD EDGE are trademarks of Inseego Corp. Other company, product, or service names mentioned herein are the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220719005500/en/
Contact information
Inseego Corp. Media Contact
Anette Gaven
Tel: +1 (619) 993-3058
Email: Anette.Gaven@inseego.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom